Clinical Trial Update: A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease [Phase 2]

View source ↗

Summary

Phase 2a/b trial update describing subcutaneous amlitelimab for adults with nonresponsive celiac disease, sponsored by Sanofi, currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• Amlitelimab (amlitelimab)

Snippet

Sponsor: Sanofi | Conditions: Coeliac Disease, Celiac Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING